Matches in Wikidata for { <http://www.wikidata.org/entity/Q92616337> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- Q92616337 description "artículu científicu espublizáu en payares de 2018" @default.
- Q92616337 description "im November 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q92616337 description "scientific article published on 08 November 2018" @default.
- Q92616337 description "wetenschappelijk artikel" @default.
- Q92616337 description "наукова стаття, опублікована в листопаді 2018" @default.
- Q92616337 name "Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy" @default.
- Q92616337 name "Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy" @default.
- Q92616337 type Item @default.
- Q92616337 label "Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy" @default.
- Q92616337 label "Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy" @default.
- Q92616337 prefLabel "Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy" @default.
- Q92616337 prefLabel "Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy" @default.
- Q92616337 P1433 Q92616337-8284952A-B8DD-44EF-A301-C2B20C17E719 @default.
- Q92616337 P1476 Q92616337-CFBE5C77-385D-4FA3-87F2-53B495BAD918 @default.
- Q92616337 P2093 Q92616337-13738190-8B69-4D00-B048-E5C3823E6466 @default.
- Q92616337 P2093 Q92616337-23E594FA-5793-4142-BA52-5779D8B5354D @default.
- Q92616337 P2093 Q92616337-407B7296-2AF7-48B9-B8DA-D0EA5A94A856 @default.
- Q92616337 P2093 Q92616337-41004418-8C09-4E73-A984-58D5E42FA58E @default.
- Q92616337 P2093 Q92616337-5FB68DC4-AE43-4AE8-925B-098003AA0465 @default.
- Q92616337 P2093 Q92616337-6446FCE3-9529-4621-9870-8F0F648F5586 @default.
- Q92616337 P2093 Q92616337-79578956-DA98-4DD4-AC46-1E83674E173D @default.
- Q92616337 P2093 Q92616337-B1684636-562B-4213-9CA0-23DEB662F2D3 @default.
- Q92616337 P2093 Q92616337-D402917A-5652-43C6-8ACD-419A30FDEEB0 @default.
- Q92616337 P2093 Q92616337-DD19C29A-21A3-4043-9D2B-09A8A2651D45 @default.
- Q92616337 P2093 Q92616337-EE923A1B-3E38-47B5-83C1-FF63D7BBF21E @default.
- Q92616337 P2093 Q92616337-FF14F157-1182-4EE0-8FB4-93516FEA285F @default.
- Q92616337 P304 Q92616337-C3CE3931-840E-4A26-ABA5-9573F9D88196 @default.
- Q92616337 P31 Q92616337-2EC4DF76-AD44-4434-9449-59AB7BF04E3F @default.
- Q92616337 P356 Q92616337-79A3D2A7-5EBA-46EF-9778-73CDBF5975F8 @default.
- Q92616337 P433 Q92616337-716D9F00-73A5-4E64-A614-6311D999E9C3 @default.
- Q92616337 P478 Q92616337-90240B46-9988-4E1F-BB39-0E99A1D55E6A @default.
- Q92616337 P577 Q92616337-D137635C-1A8F-4803-9D80-E1AC728C62C7 @default.
- Q92616337 P698 Q92616337-AA2DCEA7-B9F0-4E95-8859-D3A0796A22AD @default.
- Q92616337 P921 Q92616337-23EFD76B-34F5-45FD-BD82-15A644416F47 @default.
- Q92616337 P356 J.EUO.2018.09.009 @default.
- Q92616337 P698 31412011 @default.
- Q92616337 P1433 Q63882907 @default.
- Q92616337 P1476 "Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy" @default.
- Q92616337 P2093 "Haojie Li" @default.
- Q92616337 P2093 "James Pellissier" @default.
- Q92616337 P2093 "Karl Patterson" @default.
- Q92616337 P2093 "Natalie Zarabi" @default.
- Q92616337 P2093 "Petros Grivas" @default.
- Q92616337 P2093 "Rachael Batteson" @default.
- Q92616337 P2093 "Ronald de Wit" @default.
- Q92616337 P2093 "Ruifeng Xu" @default.
- Q92616337 P2093 "Stephen Keefe" @default.
- Q92616337 P2093 "Vimalanand Prabhu" @default.
- Q92616337 P2093 "Yang Meng" @default.
- Q92616337 P2093 "Yichen Zhong" @default.
- Q92616337 P304 "565-571" @default.
- Q92616337 P31 Q13442814 @default.
- Q92616337 P356 "10.1016/J.EUO.2018.09.009" @default.
- Q92616337 P433 "5" @default.
- Q92616337 P478 "2" @default.
- Q92616337 P577 "2018-11-08T00:00:00Z" @default.
- Q92616337 P698 "31412011" @default.
- Q92616337 P921 Q13896859 @default.